Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Splenomegaly 1Primary Myelofibrosis 1Neoplasm Metastasis 1Melanoma 1Leukemia 1Epidermolysis Bullosa Dystrophica 1Carcinoma, Squamous Cell 1Carcinoma, Non-Small-Cell Lung 1Anemia 1Adenocarcinoma 1

Interventions

Radiosurgery 79Capecitabine 77Oxaliplatin 74Fluorouracil 69Bevacizumab 69Gemcitabine 67Leucovorin 61pembrolizumab 53Nivolumab 53Paclitaxel 48Irinotecan 47Radiotherapy 45Cisplatin 44Everolimus 38Magnetic Resonance Spectroscopy 36Drug Therapy 36Docetaxel 36Cyclophosphamide 35Cetuximab 35Ipilimumab 32Carboplatin 32Trastuzumab 31Sunitinib 30Sorafenib 26Erlotinib Hydrochloride 25Doxorubicin 23Surveys and Questionnaires 20Surgical Procedures, Operative 20Specimen Handling 20Biopsy 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Neoplasm Metastasis × ON 01910 × Clear all
NCT04263090 2024-05-09

Rigosertib Plus Nivolumab for KRAS+ NSCLC Patients Who Progressed on First-Line Treatment

Icahn School of Medicine at Mount Sinai

Phase 1/2 Completed
25 enrolled
Thoracic

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡